High-Grade B-Cell Lymphoma (HGBL) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report

High-grade B-cell lymphoma (HGBL) is a newly introduced classification in the 2016 World Health Organization (WHO) revision. It replaces “B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL) (BCLU, DLBCL/BL).” HGBL includes two types: HGBL with MYC and BCL2 and BCL6 rearrangements (HGBL, R or double/triple-hit lymphoma) and high-grade B-cell lymphomas not otherwise specified (HGBL, NOS). HGBL NOS lacks MYC and BCL2 or BCL6 gene rearrangements but has morphological features between DLBCL and BL. Patients with HGBL typically present with widespread disease involvement. HGBL, NOS is considered a gray zone lymphoma, encountered infrequently in clinics, with unclear etiology and pathogenesis. DLBCL/HGBL-MYC/BCL2 are aggressive lymphomas with an unfavorable prognosis. BCL2 and BCL6 rearrangements independently negatively impact survival, especially in the first two years. DLBCL-like morphology has a better prognosis than Burkitt-like morphology. Fluorescence in situ hybridization (FISH) is the gold standard for detecting double-hit lymphoma (DHL) or triple-hit lymphoma (THL). However, there has yet to be a consensus on the criteria for selecting cases for FISH. In practice, the decision for ancillary testing like FISH is typically based on morphological interpretation by pathologists. However, this is challenging for DHL or THL due to their heterogeneous morphological features.

Thelansis’s “High-Grade B-Cell Lymphoma (HGBL) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential High-Grade B-Cell Lymphoma (HGBL) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of High-Grade B-Cell Lymphoma (HGBL) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

High-Grade B-Cell Lymphoma (HGBL) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: High-Grade B-Cell Lymphoma (HGBL) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033